Israel Englander Esperion Therapeutics, Inc. Call Options Transaction History

Millennium Management LLC

5 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q2 2024 Aug 14, 2024	BUY	$1.84 - $3.24 $552,000 - $972,000	300,000 New	300,000 $666,000
Q4 2023 Feb 14, 2024	SELL	$0.73 - $3.08 $4,015 - $16,940	-5,500 Reduced 2.75%	194,500 $581,000
Q2 2023 Aug 14, 2023	SELL	$1.2 - $1.76 $360,000 - $528,000	-300,000 Reduced 60.0%	200,000 $278,000
Q1 2023 May 15, 2023	BUY	$1.46 - $7.3 $368,650 - $1.84 Million	252,500 Added 102.02%	500,000 $795,000
Q4 2022 Feb 14, 2023	BUY	$5.09 - $8.5 $1.26 Million - $2.1 Million	247,500 New	247,500 $1.54 Million

199

136M

2.72M

1.3M

Ticker ESPR
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 66,551,600
Market Cap $127M
Description
Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascul...

Get notified when there are updates to the investment portfolio of Millennium Management LLC, based on Form 13F filings with the SEC.

Stay updated on Millennium Management LLC and Israel Englander with notifications on news.